AI Article Synopsis
- The study focused on using the cytoplasmic kappa/lambda ratio of CD138-positive plasma cells to differentiate between reactive plasmacytosis and plasma cell myeloma (PCM).
- A retrospective analysis involved 50 PCM patients and 50 controls, utilizing a novel image analysis method to measure the expression of cytoplasmic light chains in bone marrow samples.
- Results indicated that a kappa/lambda ratio cut-off of 0.35 to 5.5 achieved 100% sensitivity and 98% specificity, suggesting its potential as an effective diagnostic tool for PCM.
Article Abstract
For differentiating reactive plasmacytosis from clonal plasma cell neoplasms such as plasma cell myeloma (PCM), it is important to determine the expression of the cytoplasmic light chain accurately. Through retrospective analysis, we studied the cytoplasmic kappa/lambda ratio of CD138-positive plasma cells in bone marrow from 50 patients with PCM and 50 controls by immunohistological analysis. The percentage of cytoplasmic light chain immunoreactive cells out of the total plasma cell population was shown by a novel quantitative image analysis approach using an Aperio ScanScope CS and the Membrane v9 algorithm. PCM cells were distinguished from normal plasma cells by cut-off levels between 0.35 and 5.5, a sensitivity of 100% and a specificity of 98.0%. Detection of the cytoplasmic kappa/lambda ratio of CD138-positive plasma cells could be a useful tool for simple, efficient and accurate diagnosis of PCM.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3109/10428194.2012.685734 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Phase I Clinical Trial of High Doses of Seleno-L-methionine in Combination with Axitinib in Patients with Previously Treated Metastatic Clear Cell Renal Cell Carcinoma.
Clin Cancer Res
January 2025
Roswell Park Cancer Institute, Buffalo, NY, United States.
Background: Data in clear cell renal cell carcinoma (ccRCC) xenografts defined the seleno-L-methionine (SLM) dose and the plasma selenium concentrations associated with the enhancement of HIF1α/2α degradation, stabilization of tumor vasculature, enhanced drug delivery, and efficacy of axitinib. The data provided the rationale for the development of this phase I clinical trial of SLM and axitinib in advanced or metastatic relapsed ccRCC.
Patients And Methods: Patients were ≥18 years with histologically and radiologically confirmed advanced or metastatic ccRCC who had received at least one prior systemic therapy, which could include axitinib (last dose ≥6 months prior to enrollment).
Laser Wakefield Acceleration of Ions with a Transverse Flying Focus.
Phys Rev Lett
December 2024
Stanford University, Department of Mechanical Engineering, Stanford, California 94305, USA.
The extreme electric fields created in high-intensity laser-plasma interactions could generate energetic ions far more compactly than traditional accelerators. Despite this promise, laser-plasma accelerator experiments have been limited to maximum ion energies of ∼100 MeV/nucleon. The central challenge is the low charge-to-mass ratio of ions, which has precluded one of the most successful approaches used for electrons: laser wakefield acceleration.
View Article and Find Full Text PDFMultiple Myeloma: Improved Outcomes Resulting from a Rapidly Expanding Number of Therapeutic Options.
Target Oncol
January 2025
Berenson Cancer Center, West Hollywood, CA, USA.
Multiple myeloma (MM) is a bone-marrow-based cancer of plasma cells. Over the last 2 decades, marked treatment advances have led to improvements in the overall survival (OS) of patients with this disease. Key developments include the use of chemotherapy, immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies.
View Article and Find Full Text PDFMitochondria-plasma membrane contact sites regulate the ER-mitochondria encounter structure.
J Cell Sci
January 2025
Department of Molecular Biosciences, Northwestern University, Evanston, IL 60208, USA.
Cells form multiple, molecularly distinct membrane contact sites (MCSs) between organelles. Despite knowing the molecular identity of several of these complexes, little is known about how MCSs are coordinately regulated in space and time to promote organelle function. Here, we examined two well-characterized mitochondria-ER MCSs - the ER-Mitochondria encounter structure (ERMES) and the mitochondria-ER-cortex anchor (MECA).
View Article and Find Full Text PDFTranexamic dosing for major joint arthroplasty in adult patients with chronic kidney disease: A pharmacokinetic study and new dosing regimen.
Anesthesiology
January 2025
Department of Anesthesiology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Background: Tranexamic acid is an anti-fibrinolytic agent routinely used during hip and knee joint replacement surgery to minimize bleeding. Chronic kidney disease is a common chronic health problem seen among adults requiring major arthroplasty surgery. Tranexamic acid is renally cleared and may accumulate in chronic kidney disease.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!